Stock Events

BiomX 

$0
0
+$0+0% Wednesday 16:41

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
129,572
Avg. Volume
-
Mkt Cap
24.99M
P/E Ratio
0
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHGEW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to develop therapies similar to BiomX's phage-based treatments.
Editas Medicine
EDIT
Mkt Cap455.6M
Editas Medicine operates in the gene editing space, directly competing with BiomX's approach to treating diseases by targeting specific genetic elements.
Intellia Therapeutics
NTLA
Mkt Cap2.49B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing field, offering potential competition in developing genetic treatments.
Sangamo Therapeutics
SGMO
Mkt Cap94.38M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, competing with BiomX's genomic approaches to disease treatment.
Adverum Biotechnologies
ADVM
Mkt Cap164.19M
Adverum Biotechnologies specializes in gene therapy for serious ocular and rare diseases, potentially overlapping with BiomX's therapeutic areas.
Bluebird bio
BLUE
Mkt Cap133.39M
bluebird bio is focused on gene therapy, gene editing, and cancer immunotherapy, competing in the broader field of genetic treatments.
Beam Therapeutics
BEAM
Mkt Cap2.21B
Beam Therapeutics uses base editing, a form of gene editing, presenting competition in the precision genetic medicine space.
Voyager Therapeutics
VYGR
Mkt Cap477.03M
Voyager Therapeutics specializes in gene therapy, particularly for neurodegenerative diseases, which could compete with BiomX's phage therapy in certain applications.
Fate Therapeutics
FATE
Mkt Cap410.93M
Fate Therapeutics is working on programmed cellular immunotherapies, a different but competing approach to treating diseases at the genetic level.
Regenxbio
RGNX
Mkt Cap629M
REGENXBIO is a leader in gene therapy, using its NAV Technology Platform to develop treatments that could compete with BiomX's offerings.

About

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Show more...
CEO
Employees
58
Country
US
ISIN
US09090D1110

Listings